The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Biomarkers in COVID-19: An Up-To-Date Review
Open accessAbstract
The ongoing pandemic of coronavirus disease 2019 (COVID-19) poses several challenges to clinicians. Timely diagnosis and hospitalization, risk stratification, effective utilization of intensive care services, selection of appropriate therapies, monitoring and timely discharge are essential to save the maximum number of lives. Clinical assessment is indispensable, but laboratory markers, or biomarkers, can provide additional, objective information which can significantly impact these components of patient care. COVID-19 is not a localized respiratory infection but a multisystem disease caused by a diffuse systemic process involving a complex interplay of the immunological, inflammatory and coagulative cascades. The understanding of what the virus does to the body and how the body reacts to it has uncovered a gamut of potential biomarkers. This review discusses the different classes of biomarkers – immunological, inflammatory, coagulation, hematological, cardiac, biochemical and miscellaneous – in terms of their pathophysiological basis followed by the current evidence. Differences between children and adults are highlighted. The role of biomarkers in the diagnosis and management of Multisystem Inflammatory Syndrome in Children (MIS-C) is reviewed. The correlation of biomarkers with clinical and radiological features and the viral load, temporal evolution and the effect of treatment remain to be studied in detail. Which biomarker needs to be evaluated when and in whom, and how best this information can contribute to patient care are questions which currently lack convincing answers. With the evidence currently available broad guidelines on the rational use of available biomarkers are presented. Integrating clinical and laboratory data, monitoring trends rather than a single value, correlating with the natural course of the disease and tailoring guidelines to the individual patient and healthcare setting are essential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
Epidemiology of COVID-19 Among Children in China
Dong, Y., Mo, X., Hu, Y., Qi, X., Jiang, F., Jiang, Z., & Tong, S. (2020) · Pediatrics · doi:10.1542/peds.2020-0702 · Cited by 4,090
Multisystem Inflammatory Syndrome in U.S. Children and Adolescents
Feldstein, L. R., Rose, E. B., Horwitz, S. M., Collins, J. P., Newhams, M. M., Son, M. B. F., Newburger, J. W., Kleinman, L. C., Heidemann, S. M., Martin, A. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021680 · Cited by 2,643
Henry, B. M., de Oliveira, M. H. S., Benoit, S., Plebani, M., & Lippi, G. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-0369 · Cited by 1,964
Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study
Tan, L., Wang, Q., Zhang, D., Ding, J., Huang, Q., Tang, Y.-Q., Wang, Q., & Miao, H. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0148-4 · Cited by 1,690
Hematological findings and complications of COVID‐19
Terpos, E., Ntanasis‐Stathopoulos, I., Elalamy, I., Kastritis, E., Sergentanis, T. N., Politou, M., Psaltopoulou, T., Gerotziafas, G., & Dimopoulos, M. A. (2020) · American Journal of Hematology · doi:10.1002/ajh.25829 · Cited by 1,673
D‐dimer levels on admission to predict in‐hospital mortality in patients with Covid‐19
Zhang, L., Yan, X., Fan, Q., Liu, H., Liu, X., Liu, Z., & Zhang, Z. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14859 · Cited by 1,347
The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19
Consiglio, C. R., Cotugno, N., Sardh, F., Pou, C., Amodio, D., Rodriguez, L., Tan, Z., Zicari, S., Ruggiero, A., Pascucci, G. R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.016 · Cited by 919
COVID-19 and multisystem inflammatory syndrome in children and adolescents
Jiang, L., Tang, K., Levin, M., Irfan, O., Morris, S. K., Wilson, K., Klein, J. D., & Bhutta, Z. A. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30651-4 · Cited by 826
Cited by
Biomarkers of post-covid depression
Lorkiewicz, P., & Waszkiewicz, N. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184142 · Cited by 102
Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients
Pietrobon, A. J., Andrejew, R., Custódio, R. W. A., Oliveira, L. D. M., Scholl, J. N., Teixeira, F. M. E., de Brito, C. A., Glaser, T., Kazmierski, J., Goffinet, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1012027 · Cited by 23
Metadata
- Authors
- Samprathi, M., & Jayashree, M.
- Venue
- Frontiers in Pediatrics
- Publisher
- Frontiers Media SA
- Published
- 2021-03-30
- Volume
- 8
- Pages
- 607647-607647
- ISSN
- 2296-2360 (ISSN-L)
- OpenAlex
- W3150010507
- Cited by
- 290
- References
- 83
- FWCI
- 19.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biomarkers in COVID-19: An Up-To-Date Review. https://app.cochat.ai/papers/10.3389/fped.2020.607647
- The paper
- Samprathi, M., & Jayashree, M. (2021). Biomarkers in COVID-19: An Up-To-Date Review. Frontiers in Pediatrics. https://doi.org/10.3389/fped.2020.607647
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.